Clinical Trial Search

Primary: Adjusted Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Visual Analog Scale (VAS) at Day 15 — -26.1; -28.4; -26.2 Units on a scale — p=0.3628

Primary: Number of Participants With Clinical Efficacy — 8; 29; 18; 5 participants

Primary: Wound Appearance — 19; 19; 16.9; 14.5 units on a scale

Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants

Primary: Mean Change in Clinical Severity Score — 2.26; 3.57 units on a scale — p=<0.05

Primary: Change From Baseline in Extent of Presence/Absence of Epithelial Tongue. — NA; NA participants

Primary: Exercise Endurance Time — 490; 333; 472; 362 seconds — p=< 0.05

Primary: Seizure Free Rate: Percentage of Participants Who Did Not Have Any Seizure Episode Within the Last Month of the Maintenance Period (ie, Month 4). — 88.57; 65.00…

Primary: Change in Baseline to 2 Weeks ADHD Rating Scale — 0; 0 percentage of change

Primary: Level of Pain/Heat in the Lower Extremities Scored by the Participants on the Visual Analog Scale (VAS) Following Intra-arterial Administration of ISOVUE-250 or…

Primary: Percentage of Participants With Residual Neuromuscular Blockade (NMB)(Train of Four [TOF] Ratio <0.9) at Time of Tracheal Extubation — 56 percentage of participants

Primary: Seroprotection Rate: Anti-PRP Antibodies — 100; 100 percentage of subjects

Primary: Pain Intensity Score at Day 15 — 6.61 cm

Primary: Time-to-onset of Heartburn Relief — 30.0; 60.0 Minutes — p=<0.0480

Primary: Change From Baseline in Peak Walking Time (PWT) at Day 180 — 0.241; 0.134 Log Minutes — p=0.076